Genomic reiterated at outperform by JMP

JMP Research analyst Charles C. Duncan reiterated Genomic Health, Inc. at market outperform. A recently conducted nationwide survey of physicians who are responsible for making treatment decisions for breast-cancer patients suggests a high awareness of Oncotype DX and strongly positive experience with the genetic test that surpassed expectations. Key takeaways are that Oncotype DX is seen as a value-added tool with ample clinical validation that has the potential to become standard-of-care in forming treatment plans in node negative, estrogen receptor positive breast-cancer patients. Shares of the Redwood City, Calif.-based biotechnology company were up 75 cents, or 5.98%, at $13.30 on volume of 335,765 shares versus the three-month running average of 119,131 shares. (Nasdaq: GHDX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.